Top

Published in:

01-12-2012 | Short Communication

A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia

Authors: Fábio Morato de Oliveira, Leonardo de Carvalho Palma, Roberto Passetto Falcão, Belinda Pinto Simões

Published in: Medical Oncology | Issue 4/2012

Abstract

Chronic myelogenous leukemia (CML) is a common myeloproliferative disease that is characterized by the clonal expansion of marrow stem cells, and is associated with the Philadelphia chromosome. As the disease progresses, additional chromosome abnormalities may arise. The prognostic impact of secondary chromosomal abnormalities in CML is complex, heterogeneous, and sometimes related to previous treatment. Here, we describe a CML patient in lymphoid blast crisis associated with a new chromosomal abnormality identified, dic(7;12)(p12.21;p12.2) and i(12)(q10) using classical cytogenetics and spectral karyotype analysis. To the best of our knowledge, this is the first report of t(7;12)(p11.1;q11.1) and i(12)(q10) in a CML patient with lymphoid evolution.

Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–22.PubMedCrossRef

Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–64.PubMedCrossRef

Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.PubMedCrossRef

Hagemeijer A. Chromosomal abnormalities in CML. Baillieres Clin Haematol. 1987;1:963–81.PubMedCrossRef

Zhao L, Khan Z, Hayes L, Glassman A. Interphase fluorescence in situ hybridization analysis: a study using centromeric probes 7, 8 and 12. Ann Clin Lab Sci. 1998;28:51–6.PubMed

Ilaria RL Jr. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology Am Soc Hematol Educ Program. 2005;188–94.

Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, et al. Randomized comparison of interferon-alpha with bussulphan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84(12):4064–77.PubMed

Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosom Cancer. 1991;3(1):1–7.PubMedCrossRef

Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN (2009): an international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger; 2009.

10.

Wang Y, Hopwood VL, Hu P, Lennon A, Osterberger J, Glassman A. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia. Cancer Genet Cytogenet. 2004;153(1):53–6.PubMedCrossRef

11.

Watmore AE, Potter AM, Sokol RJ, Wood JK. Value of cytogenetic studies in prediction of acute phase CML. Cancer Genet Cytogenet. 1985;14(3–4):293–301.PubMedCrossRef

12.

Swolin B, Weinfeld A, Westin J, Waldenström J, Magnusson B. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet. 1985;18(1):65–79.PubMedCrossRef

13.

Schröck E, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273:494–7.PubMedCrossRef

14.

Veldman T, Vignon C, Schrock E, Rowley JD, Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet. 1997;15:406–10.PubMedCrossRef

15.

Oliveira FM, Lucena-Araújo AR, Leite-Cueva SD, Santos GA, Rego EM, Falcão RP. Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype. Cancer Genet Cytogenet. 2010;198(1):62–5.PubMedCrossRef

16.

Oliveira FM, Falcão RP, de Figueiredo Pontes LL, Simões BP, Tone LG. Insertion (15;14)(q22;q13q32) in a case of Ph+ ALL. Cancer Genet Cytogenet. 2008;185(1):65–7.PubMedCrossRef

17.

Johnson E, Cotter FE. Monosomy 7 and 7q associated with myeloid malignancy. Blood Rev. 1997;11:46–55.PubMedCrossRef

18.

Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia. 2001;15:1689–95.PubMedCrossRef

19.

Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol. 2005;15:162–74.PubMedCrossRef

20.

Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood. 2000;96(1):358–61.PubMed

21.

Boultwood J, Fidler C, Shepherd P, Watkins F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket AJ, Wainscoat JS. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol. 1999;61(1):5–9.PubMedCrossRef

22.

Keller G, Brassat U, Braig M, Heim D, Wege H, Brümmendorf TH. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol Oncol. 2009;27(3):123–9.PubMedCrossRef

Title: A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia
Authors: Fábio Morato de Oliveira
Leonardo de Carvalho Palma
Roberto Passetto Falcão
Belinda Pinto Simões
Publication date: 01-12-2012
Publisher: Springer US
Published in: Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-0142-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis

Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells

Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis

Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma

Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page